# Hyperion Defi, Inc.: Form 10-Q for the period ended Jun 30, 2018

- Company: [Hyperion Defi, Inc.](/companies/hypd.md) (CIK 1682639)
- Form: 10-Q
- Filed: 2018-08-14
- Accepted by EDGAR: Aug 14, 2018, 14:45 ET
- Period: 2018-06-30
- Accession: 0001144204-18-044570
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1682639/000114420418044570/tv500003_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1682639/000114420418044570/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2018-04-01 to 2018-06-30 | $2.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2018-01-01 to 2018-06-30 | $4.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-04-01 to 2018-06-30 | −$3.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2018-01-01 to 2018-06-30 | −$6.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2018-04-01 to 2018-06-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-01-01 to 2018-06-30 | −$6.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-04-01 to 2018-06-30 | −$0.33 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2018-01-01 to 2018-06-30 | −$0.77 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2018-01-01 to 2018-06-30 | −$5.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2018-01-01 to 2018-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-06-30 | $24.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-06-30 | $24.8m | us-gaap:AssetsCurrent |
| Total assets | at 2018-06-30 | $24.8m | us-gaap:Assets |
| Current liabilities | at 2018-06-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2018-06-30 | $23.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,987 characters.

*The following discussion and analysis of the results of operations and financial condition of Eyenovia, Inc. (“Eyenovia,” the “Company,” “we,” “us” and “our”) as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017 should be read in conjunction with our unaudited financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (“SEC”).*

### Forward Looking Statements

This report contains “forward-looking statements.” Specifically, all statements other than statements of historical facts included in this report regarding our financial position, business strategy and plans and objectives of management for future operations are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “might,” “will,” “continue” “intend,” and “plan” and words or phrases of similar import, as they relate to our financial position, business strategy and plans, or objectives of management, are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors” included in our most recent Annual report on Form 10-K filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of our Annual Report on Form 10-K. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

### Overview

We are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-doses (6–8 µL) of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye. This micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers) that routinely overdose or under-dose when used in the topical administration of ophthalmic therapeutics. We believe our micro-therapeutic product candidates may be able to achieve similar pharmacologic effects as traditional macro-dosing applications while reducing the adverse effects associated with these techniques. We have received written FDA feedback indicating that we can proceed to Phase III clinical trials for two of our lead programs: MicroProst, a novel micro-therapeutic latanoprost formulation for Chronic Angle Closure Glaucoma (CACG), an indication with no FDA-approved drug treatments; and MicroStat, a fixed combination of micro-therapeutic phenylephrine-tropicamide formulation for mydriasis, also known as pupil dilation for use in eye exams. MicroTears, our OTC product candidate for dry eye, will not require Phase III clinical trials, and we plan to proceed with registration activities.

We have completed two Phase II clinical trials, treating more than 110 subjects, with results published in peer-reviewed literature. Applying multiple front-of-the-eye (the area in front of the lens) formulations in subjects for mydriasis, our piezo-print technology delivered microliter precision at the volume of the eye’s natural tear film capacity of 6–8 µL, which reduced ocular and systemic drug and preservative exposure when compared to eye drops, resulting in comparable efficacy with fewer side effects. We believe that these clinical trials support our advancement into late stage clinical trials utilizing the 505(b)(2) pathway. We intend to use this pathway for future clinical trials in new indications with significant unmet needs. We plan to commence Phase III clinical trials for MicroProst (in the first half of 2019) and MicroStat (in the second half of 2018), pending IND submission and FDA feedback.

We have not completed development of any product candidate and we have therefore not generated any revenues from product sales.

Historically, we have financed our operations principally through private placements of preferred stock as well as our initial public offering that closed in January 2018. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating requirements for at least the next twelve months. Thereafter, the Company will need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs.

Our net losses were $3.3 million and $6.7 million for the three and six months ended June 30, 2018, respectively. As of June 30, 2018, we had working capital and an accumulated deficit of $23.6 million and $26.0 million, respectively.

### Financial Overview

#### Revenue

We have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. Our ability to generate revenues will depend heavily on the successful development, regulatory approval and commercialization of our micro-therapeutic product candidates.

#### Research and Development Expenses

Research and development expenses are incurred in connection with the research and development of our micro-therapeutics and consist primarily of contract service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:

- direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;
- personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and
- facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities.

We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.

We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.

#### General and Administrative Expenses

General and administrative expenses consist primarily of payroll and related expenses, legal and other professional services, as well as non-cash stock-based compensation expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and the potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with being a public company are expected to increase in future periods.

### Results of Operations

### Three Months Ended June 30, 2018 Compared with Three Months Ended June 30, 2017

#### Research and Development Expenses

Research and development expenses for the three months ended June 30, 2018 totaled $2.4 million, an increase of $1.7 million, or 221%, as compared to $0.8 million recorded for the three months ended June 30, 2017. Research and development expenses consisted of the following:

|  | For the Three Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: |
| Direct clinical and non-clinical expenses | $1,123,115 | $708,711 |
| Personnel-related expenses | 629,776 | 17,130 |
| Non-cash stock-based compensation expenses | 11,369 | 3,094 |
| Facilities and other expenses | 647,904 | 22,995 |
| Total research and development expenses | $2,412,164 | $751,930 |

The increase in direct clinical and non-clinical expenses, facilities and other expenses and personnel-related expenses is primarily due to an increase in contracted services, supplies and the hiring of twelve additional employees as we expanded our research and development activities for our micro-therapeutic products. For the three months ended June 30, 2018, personnel-related expenses include approximately $0.1 million of estimated expenses in connection with year-end 2018 executive bonuses that have yet to have been paid. The increase in non-cash stock-based compensation expense as compared to the 2017 period was due to an additional 581,532 and 81,500 stock options that were granted in July 2017 and April 2018, respectively.

#### General and Administrative Expenses

General and administrative expense for the three months ended June 30, 2018 totaled $0.9 million, an increase of $0.7 million, or 304%, as compared to $0.2 million recorded for the three months ended June 30, 2017. This increase was primarily attributable to an increase in expenses related to payroll and contracted services of $0.3 million (including approximately $0.1 million of estimated expenses in connection with year-end 2018 executive bonuses that have yet to have been paid), professional fees of $0.2 million and insurance expense of $0.1 million. It also was largely due to the hiring of an additional 4 employees associated with the growth of our business as well as costs related to being a public company.

### Six Months Ended June 30, 2018 Compared with Six Months Ended June 30, 2017

#### Research and Development Expenses

Research and development expenses for the six months ended June 30, 2018 totaled $4.5 million, an increase of $2.8 million, or 171%, as compared to $1.7 million recorded for the six months ended June 30, 2017. Research and development expenses consisted of the following:

|  | For the Six Months Ended June 30, 2018 | 2017 |
| --- | ---: | ---: |
| Direct clinical and non-clinical expenses | $2,189,391 | $1,590,947 |
| Personnel-related expenses | 1,050,992 | 17,130 |
| Non-cash stock-based compensation expenses | 316,290 | 6,431 |
| Facilities and other expenses | 949,586 | 48,264 |
| Total research and development expenses | $4,506,259 | $1,662,771 |

The increase in direct clinical and non-clinical expenses, facilities and other expenses and personnel-related expenses is primarily due to an increase in contracted services, supplies and the hiring of twelve additional employees as we expanded our research and development activities for our micro-therapeutic products. For six months ended June 30, 2018, personnel-related expenses include approximately $0.1 million of estimated expenses in connection with year-end 2018 executive bonuses that have yet to have been paid. The increase in non-cash stock-based compensation expense as compared to the 2017 period was due to an additional 581,532 and 81,500 stock options that were granted in July 2017 and April 2018, respectively.

#### General and Administrative Expenses

General and administrative expense for the six months ended June 30, 2018 totaled $2.2 million, an increase of $1.8 million, or 434%, as compared to $0.4 million recorded for the six months ended June 30, 2017. This increase was primarily attributable to an increase in professional fees of $0.7 million, non-cash stock-based compensation costs of $0.3 million, and expenses related to payroll and contracted services of $0.6 million (including approximately $0.1 million of estimated expenses in connection with year-end 2018 executive bonuses that have yet to have been paid), as compared to 2017. It also was largely due to the hiring of an additional 4 employees associated with the growth of our business as well as costs related to being a public company.

### Liquidity and Capital Resources

Since inception, we have experienced negative cash flows from operations. At June 30, 2018, our accumulated deficit since inception was $26.0 million. In January 2018, we raised aggregate net proceeds of $24.7 million in connection with our initial public offering.

At June 30, 2018, we had total current assets of $24.8 million and current liabilities of $1.3 million, resulting in working capital of $23.5 million. At June 30, 2018, we had total assets of $24.8 million and total liabilities of $1.3 million, resulting in stockholders’ equity of $23.5 million.

At June 30, 2018 and December 31, 2017, we had no debt outstanding.

At June 30, 2018, we had a cash balance of $24.6 million. We expect our current cash on hand to be sufficient to meet our operating and capital requirements for at least the next twelve months from the date of this filing. Thereafter, we will likely need to raise further capital, through the sale of additional equity or debt securities, to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.

During the six months ended June 30, 2018 and 2017, our sources and uses of cash were as follows:

Net cash used in operating activities for the six months ended June 30, 2018 was $5.4 million, which includes cash used to fund a net loss of $6.7 million, reduced by $0.7 of non-cash stock compensation, partially offset by $0.6 million of cash provided by changes in operating assets and liabilities. Net cash used in operating activities for the six months ended June 30, 2017 was $1.9 million, which includes cash used to fund a net loss of $2.1 million, partially offset by $0.1 million of cash provided by changes in operating assets and liabilities.

There were no cash flows from investing activities for the six months ended June 30, 2018. Cash used in investing activities was approximately $10,000 for the six months ended June 31, 2017, which was attributable to purchases of property and equipment.

Cash provided by financing activities for the six months ended June 30, 2018 totaled $24.7 million, which was primarily attributable to $25.1 million of proceeds from the sale of common stock in our initial public offering, reduced by issuance costs related to our initial public offering of $0.4 million. There were no cash flows from financing activities for the six months ended June 30, 2017.

### Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

### Critical Accounting Policies

For a description of our critical accounting policies, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

### Recently Adopted Accounting Pronouncements

For a description of recently adopted accounting pronouncements, including adoption dates and estimated effects, if any, on our consolidated financial statements, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

## Controls and procedures

As filed, 4,129 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on the foregoing evaluation, our principal executive officer and principal financial and accounting officer concluded that, as of June 30, 2018, our disclosure controls and procedures were not effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure, due to the material weaknesses described below.

Our Annual Report on Form 10-K did not include a report of management’s assessment regarding internal control over financial reporting as of December 31, 2017 or an attestation report of our registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies and emerging growth companies, as applicable. However, the following material weaknesses in our internal control over financial reporting were identified as of December 31, 2017 in the normal course and continued to exist as of June 30, 2018:

1\. We had insufficient segregation of duties in our finance and accounting function because of our limited personnel.

2\. We did not properly identify all related party relationships and transactions so that they could be evaluated for disclosure in our public filings.

3\. The terms of certain agreements entered into by us were not properly communicated to the Board of Directors in order for the Board of Directors to take the appropriate actions.

4\. We did not adequately record research and development expenses in our internal books and records to permit timely and accurate financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard AS 2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

#### Remediation

We intend to address the weaknesses identified above by, among other things, (a) increasing the oversight and review procedures of the Board of Directors and its Audit Committee with regard to financial reporting, financial processes and procedures and internal control procedures and (b) hiring additional finance and accounting personnel, including a Chief Financial Officer (hired December 2017), who will assist in the process of remediating the weaknesses identified above. In April 2018, the Board of Directors also adopted a related party transaction policy. In July 2018, we implemented an enhanced chart of accounts designed to facilitate the timely and accurate financial reporting of research and development expenses. Our management believes that the controls implemented to-date are sufficient to address weaknesses (2), (3) and (4) above. However, no assurances that our remediation is effective can be made until remedial controls are implemented and operate for a period of time. We expect to have all the material weaknesses identified in this Item 4 remediated before the end of the year.

### Changes in Internal Control over Financial Reporting

Except as disclosed above, our internal control over financial reporting did not change during the three months ended June 30, 2018.

Filed Aug 14, 2018.
Source: SEC EDGAR, the filing index for accession 0001144204-18-044570. Last ingested by Listed: Nov 14, 2026, 10:51 ET. No prices; not investment advice.
